Clinical Trials
125 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
OvAR-Y
Washington University School of Medicine
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology Inc.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen Inc.
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
LIBRETTO-001
Eli Lilly and Company
TraveraRTGx
Travera Inc
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Institutes of Health Clinical Center (CC)
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Kaiser Permanente
ONE TEAM
Duke University
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
LIBRETTO-121
Eli Lilly and Company
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
VARTUTRACE
Var2 Pharmaceuticals
Trained Immunity in Thyroid Carcinoma and Colon Carcinoma
Radboud University Medical Center
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Takeda
LIBERATE
University Health Network, Toronto
PAVO
Tempus AI
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
AYAConnect
UNC Lineberger Comprehensive Cancer Center
DENALI-1
A2 Biotherapeutics Inc.
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
IC-Growth
Centre for Research and Technology Hellas
SPARTA
Apollomics Inc.
ARROW
Hoffmann-La Roche
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
IT-01
Intensity Therapeutics, Inc.
Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.
Cyprus University of Technology
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
HERO
Rutgers, The State University of New Jersey
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Universidade Federal de Pernambuco
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
ROOT
Taproot Health
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure, Inc.
QUANTUM
VitaMed Research LLC
Dragon
Washington University School of Medicine
OligoRARE
European Organisation for Research and Treatment of Cancer - EORTC